These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28064104)

  • 61. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
    Wagner A; Bock CT; Fechner H; Kurreck J
    Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
    [No Abstract]   [Full Text] [Related]  

  • 62. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
    Ming X
    Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Microneedles for transdermal drug delivery.
    Prausnitz MR
    Adv Drug Deliv Rev; 2004 Mar; 56(5):581-7. PubMed ID: 15019747
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of DC/mDC iontophoresis and terpenes on transdermal permeation of methotrexate: in vitro study.
    Prasad R; Koul V; Anand S; Khar RK
    Int J Pharm; 2007 Mar; 333(1-2):70-8. PubMed ID: 17116378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Transdermal drug delivery using iontophoresis and phonophoresis.
    Roberts D
    Orthop Nurs; 1999; 18(3):50-4. PubMed ID: 11052031
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combination strategies for enhancing transdermal absorption of sumatriptan through skin.
    Femenía-Font A; Balaguer-Fernández C; Merino V; López-Castellano A
    Int J Pharm; 2006 Oct; 323(1-2):125-30. PubMed ID: 16809010
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Transdermal drug delivery systems: skin perturbation devices.
    Brown MB; Traynor MJ; Martin GP; Akomeah FK
    Methods Mol Biol; 2008; 437():119-39. PubMed ID: 18369965
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transdermal Delivery of Iron Using Soluble Microneedles: Dermal Kinetics and Safety.
    Modepalli N; Shivakumar HN; McCrudden MT; Donnelly RF; Banga A; Murthy SN
    J Pharm Sci; 2016 Mar; 105(3):1196-200. PubMed ID: 26928401
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dual-Phase Iontophoresis for the Delivery of Antisense Oligonucleotides.
    Gibson DJ; Tuli SS; Schultz GS
    Nucleic Acid Ther; 2017 Aug; 27(4):238-250. PubMed ID: 28375679
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Potential use of iontophoresis for transdermal delivery of NF-kappaB decoy oligonucleotides.
    Hashim II; Motoyama K; Abd-Elgawad AE; El-Shabouri MH; Borg TM; Arima H
    Int J Pharm; 2010 Jun; 393(1-2):127-34. PubMed ID: 20417264
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cellular Targeting of Oligonucleotides by Conjugation with Small Molecules.
    Hawner M; Ducho C
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33339365
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic and therapeutic applications of iontophoresis.
    Sieg A; Wascotte V
    J Drug Target; 2009 Nov; 17(9):690-700. PubMed ID: 19845485
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A novel method to enhance the efficiency of drug transdermal iontophoresis delivery by using complexes of drug and ion-exchange fibers.
    Xin C; Li-hong W; Yue Y; Ya-nan G; Qi-fang W; Yang Y; San-ming L
    Int J Pharm; 2012 May; 428(1-2):68-75. PubMed ID: 22405965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C; Newsome JT; Mewani R; Pei J; Gokhale PC; Kasid UN
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Percutaneous penetration of anticancer agents: Past, present and future.
    Ita K
    Biomed Pharmacother; 2016 Dec; 84():1428-1439. PubMed ID: 27802901
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RNA Therapeutics: How Far Have We Gone?
    Coutinho MF; Matos L; Santos JI; Alves S
    Adv Exp Med Biol; 2019; 1157():133-177. PubMed ID: 31342441
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Biological barriers to therapy with antisense and siRNA oligonucleotides.
    Juliano R; Bauman J; Kang H; Ming X
    Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.